Vistin Pharma Asa · OSL:VISTN
Vistin Pharma Asa — Q2 2020 Earnings Presentation
20 slides from Vistin Pharma Asa's earnings presentation, Aug 28, 2020
Slide 1: Vistin Pharma - Second quarter and first half 2020
Vistin Pharma - Second quarter and first half 2020 Kjell-Erik Nordby (CEO) Alexander Karlsen (CFO) 28 August 2020 1
Slide 2: Agenda
Agenda Highlights Operational review - pharmaceuticals Financial review Outlook Appendix 2
Slide 3: Highlights: Second quarter 2020
HIGHLIGHTS Second quarter 2020 20% increase in revenue vs 2nd quarter 2019 and highest sales ever in a quarter - Revenue of MNOK 73 for the quarter vs. MNOK 61.1 in Q2 2019 - Revenue of MNOK 134.4 in first half of 2020, compared to MNOK 103.3 in first half of 2019, a growth of 30% EBITDA MNOK 20
Slide 4: 2018-2020 Strong revenue and EBITDA development
HIGHLIGHTS 2018-2020 Strong revenue and EBITDA development MNOK Revenues* 160 140 25% 134 120 107 103 100 80 60 40 20 0 1H 2018 1H 2019 1H 2020 MNOK EBITDA* 40 35 35 30 218% 25 20 15 12 11 10 5 0 1H 2018 1H 2019 1H 2020 *Only pharmaceuticals 4
Slide 5: Agenda
Agenda Highlights Operational review - pharmaceuticals Financial review Outlook Appendix 5
Slide 6: Vistin Pharma a dedicated metformin producer with a bright outlook
OPERATIONAL REVIEW - PHARMACEUTICALS Vistin Pharma a dedicated metformin producer with a bright outlook DIABETES METFORMIN A BRIGHT OUTLOOK - - FOR VISTIN PHARMA ONE OF THE THE GOLD STANDARD - LARGEST HEALTH + TREATMENT OF TYPE = A LEADING GLOBAL EMERGENCIES IN THE 2 DIABETES PRODUCER OF 21ST CENTUR
Slide 7: Diabetes – A global emergency
OPERATIONAL REVIEW - PHARMACEUTICALS Diabetes – A global emergency Diabetes in perspective: 1 of 7 births is affected by gestational diabetes 1 in 11 adults has diabetes Every 6 seconds a person dies from diabetes Number of people living with diabetes Source International Diabetes Federation
Slide 8: 6% increase in sales volume vs Q2'19
OPERATIONAL REVIEW - PHARMACEUTICALS 6% increase in sales volume vs Q2’19 Sales volume metformin (HCl & DC) 1000 900 930 915 Sales volume for the second quarter was 915MT, up by 900 866 873 6% vs Q2 2019 (866MT) 813 815 800 The production plant has been running at full capacity 700 598 608 Eff
Slide 9: Business update and Corona virus epidemic consequences
OPERATION UPDATE Business update and Corona virus epidemic consequences The Fikkjebakke plant is running at full capacity - Successful actions have been taken to secure the supply of critical raw materials and to build security stocks during the Covid-19 outbreak There are no reported corona inf
Slide 10: Agenda
Agenda Highlights Operational review - pharmaceuticals Financial review Outlook Appendix 10
Slide 11: Key quarterly figures for Vistin Pharma
FINANCIAL REVIEW Key quarterly figures for Vistin Pharma Revenue (pharmaceuticals) NOK million 80 Revenues 73 MNOK 12 (+20%) higher revenue YoY – driven by higher 68 70 sales volume and favourable EUR/NOK exchange rate 61 61 60 55 57 53 MNOK 31 (+30%) higher revenue in 1H 2020 vs 1H 2019 50 - Q1
Slide 12: Key quarterly figures for Vistin Pharma
FINANCIAL REVIEW Key quarterly figures for Vistin Pharma Results (pharmaceuticals) NOK million 25 EBITDA 20,9 20 EBITDA from pharmaceuticals MNOK 20.9 vs MNOK 13.3 in Q2 2019, an increase of 58%. 14,2 15 13,3 11,8 1H 2020 EBITDA increased by MNOK 23 vs 1H 2019, 10 6,8 (+200%). 4,4 4,9 5 EBITDA
Slide 13: Consolidated income statement
FINANCIAL REVIEW Consolidated income statement (NOK 1 000) Q2 2020 Q2 2019 YTD 2020 YTD 2019 FY 2019 Total revenue and income Pharmaceuticals 73 021 61 103 134 428 103 337 228 130 Energy Trading - - - - - HQ & other - - - - - Total revenue and income 73 021 61 103 134 428 103 337 228 130 EBITDA Phar
Slide 14: Balance sheet Vistin Pharma
FINANCIAL REVIEW Balance sheet Vistin Pharm Assets NOK 1000 30.06.2020 30.06.2019 31.12.2019 600 000 ASSETS Non-current assets 500 000 Property, plant & equipment 100 296 102 369 101 802 Right -of-use-assets 672 (0) (0) 400 000 Deferred tax assets 35 003 23 015 7 733 Total non-current assets 135 971
Slide 15: Balance sheet Vistin Pharma
FINANCIAL REVIEW Balance sheet Vistin Pharm Equity and liabilities NOK 1000 30.06.2020 30.06.2019 31.12.2019 EQUITY AND LIABILITIES 600 000 Equity Share capital 44 345 44 345 44 345 500 000 Share premium 229 056 273 401 273 401 Retained earnings (14 448) 30 743 95 649 Total equity 258 954 348 490 41
Slide 16: Agenda
Agenda Highlights Operational review - pharmaceuticals Financial review Outlook Appendix 16
Slide 17: Outlook
Outlook Outlook Metformin market expected to continue to grow by 4-5% annually - Diabetes is one of the largest health crises of the 21st century - Metformin is expected to maintain its position as the Gold Standard treatment for T2D in the foreseeable future Attractive growth potential from exi
Slide 18: Agenda
Agenda Highlights Operational review - pharmaceuticals Financial review Outlook Appendix 18
Slide 19: Top 20 shareholders as of 30 June 2020
APPENDIX Top 20 shareholders as of 30 June 2020 NAME SHAREHOLDING % SHARE INTERTRADE SHIPPING AS* 7 766 539 17,51 % PACTUM AS* 3 519 733 7,94 % HOLMEN SPESIALFOND 3 250 000 7,33 % SAGA TANKERS ASA* 2 284 280 5,15 % SPAREBANK 1 MARKETS AS 2 060 034 4,65 % MP PENSJON PK 1 752 913 3,95 % DNB Markets Ak
Slide 20: Thank you for your attention!
Thank you for your attention! www.vistin.com 20